Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 144

Similar articles for PubMed (Select 23388678)

1.

Association between risk behaviors and antiretroviral resistance in HIV-infected patients receiving opioid agonist treatment.

Tetrault JM, Kozal MJ, Chiarella J, Sullivan LE, Dinh AT, Fiellin DA.

J Addict Med. 2013 Mar-Apr;7(2):102-7. doi: 10.1097/ADM.0b013e31827f9bdf.

2.

Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care.

Chaudhry AA, Botsko M, Weiss L, Egan JE, Mitty J, Estrada B, Lucas GM, Woodson T, Flanigan TP, Fiellin DA; BHIVES Collaborative.

J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S14-21. doi: 10.1097/QAI.0b013e318209d3b9.

PMID:
21317589
3.

The medical management of opioid dependence in HIV primary care settings.

Lum PJ, Tulsky JP.

Curr HIV/AIDS Rep. 2006 Nov;3(4):195-204. Review.

PMID:
17089480
4.

Sexual risk behavior among youth with perinatal HIV infection in the United States: predictors and implications for intervention development.

Tassiopoulos K, Moscicki AB, Mellins C, Kacanek D, Malee K, Allison S, Hazra R, Siberry GK, Smith R, Paul M, Van Dyke RB, Seage GR 3rd; Pediatric HIV/AIDS Cohort Study.

Clin Infect Dis. 2013 Jan;56(2):283-90. doi: 10.1093/cid/cis816. Epub 2012 Nov 7.

5.

A population-based and longitudinal study of sexual behavior and multidrug-resistant HIV among patients in clinical care.

Kozal MJ, Amico KR, Chiarella J, Cornman D, Fisher W, Fisher J, Friedland G.

MedGenMed. 2006 Jun 13;8(2):72.

6.

Antiretroviral (ARV) drug resistance in the developing world.

Shekelle P, Maglione M, Geotz MB, Wagner G, Wang Z, Hilton L, Carter J, Chen S, Tringle C, Mojica W, Newberry S.

Evid Rep Technol Assess (Full Rep). 2007 Sep;(156):1-74. Review.

7.

[Prevalence of human immunodeficiency virus and risk behaviours among opioid users seen in an emergency room].

Pérez González K, Domingo-Salvany A, Hartnoll R.

Gac Sanit. 1999 Jan-Feb;13(1):7-15. Spanish.

8.

Effect of buprenorphine and antiretroviral agents on the QT interval in opioid-dependent patients.

Baker JR, Best AM, Pade PA, McCance-Katz EF.

Ann Pharmacother. 2006 Mar;40(3):392-6. Epub 2006 Feb 28.

PMID:
16507617
9.

Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users.

Sullivan LE, Metzger DS, Fudala PJ, Fiellin DA.

Addiction. 2005 Feb;100(2):150-8. Review.

PMID:
15679744
10.

High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1.

Richard N, Juntilla M, Abraha A, Demers K, Paxinos E, Galovich J, Petropoulos C, Whalen CC, Kyeyune F, Atwine D, Kityo C, Mugyenyi P, Arts EJ.

AIDS Res Hum Retroviruses. 2004 Apr;20(4):355-64.

PMID:
15157354
11.

High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lomé, Togo.

Dagnra AY, Vidal N, Mensah A, Patassi A, Aho K, Salou M, Monleau M, Prince-David M, Singo A, Pitche P, Delaporte E, Peeters M.

J Int AIDS Soc. 2011 Jun 10;14:30. doi: 10.1186/1758-2652-14-30.

12.

Sexual HIV risk behaviors in a treatment-refractory opioid-dependent sample.

McHugh RK, Weitzman M, Safren SA, Murray HW, Pollack MH, Otto MW.

J Psychoactive Drugs. 2012 Jul-Aug;44(3):237-42.

13.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
14.

Clinical and behavioral characteristics of adults receiving medical care for HIV infection --- Medical Monitoring Project, United States, 2007.

Blair JM, McNaghten AD, Frazier EL, Skarbinski J, Huang P, Heffelfinger JD.

MMWR Surveill Summ. 2011 Sep 2;60(11):1-20.

15.
16.

Antiretroviral resistance in HIV-infected Saudi children failing first-line highly active antiretroviral therapy.

Al Hajjar SH, Frayha H, Althawadi S.

Ann Saudi Med. 2012 Nov-Dec;32(6):565-9. doi: 10.5144/0256-4947.2012.565.

PMID:
23396017
17.

Rationale, design, and sample characteristics of a randomized controlled trial of directly observed antiretroviral therapy delivered in methadone clinics.

Berg KM, Mouriz J, Li X, Duggan E, Goldberg U, Arnsten JH.

Contemp Clin Trials. 2009 Sep;30(5):481-9. doi: 10.1016/j.cct.2009.05.003. Epub 2009 Jun 6.

18.

Access to highly active antiretroviral therapy for injection drug users: adherence, resistance, and death.

Vlahov D, Celentano DD.

Cad Saude Publica. 2006 Apr;22(4):705-18. Epub 2006 Apr 5.

19.

The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study.

Roux P, Carrieri MP, Villes V, Dellamonica P, Poizot-Martin I, Ravaux I, Spire B; MANIF2000 cohort study group.

Addiction. 2008 Nov;103(11):1828-36. doi: 10.1111/j.1360-0443.2008.02323.x. Epub 2008 Sep 4.

PMID:
18778390
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk